Judge Rejects Novo Bid to Block Lilly Obesity Ads as GLP-1 Peptide Battle Escalates
A federal judge denied Novo’s bid to block Lilly’s Wegovy vs Zepbound ads, finding no prescription decline. The ruling reframes competition in the GLP-1 peptide market.